May 2019
Price: £150 PLUS VAT
Format: DOWNLOADABLE PDF
This seminar discussed key issues in pharmaceutical pricing, access to medicines and priorities for the Voluntary Scheme for Branded Medicines Pricing and Access which succeeded the Pharmaceutical Price Regulation Scheme.
Delegates considered the impact of the new 5-year scheme on potential savings to the NHS, patient access and medicines innovation - with the Government announcing expected savings of around £930m in 2019.
Sessions assessed how industry will be affected by the Voluntary Scheme - following the introduction of a 2% cap on the growth in sales of branded medicines - as well as challenges for NICE as they aim to quicken their assessments of new medicines.
In the context of the NHS Long Term Plan - which includes goals to deliver better value from NHS expenditure on medicines whilst encouraging the adoption of proven innovations - sessions assessed options for reducing expenditure on medicines going forward and the role of NHS England in accelerating innovation.
The agenda also assessed challenges with bringing new products to the market - including the impact of the Accelerated Access Collaborative, designed to support the breakthrough of new medicine and technology.
